Genomic Health Team

The Genomic Health team at 23andMe leads innovations in genomics from the frontlines. Trained as scientific researchers, educators, and clinicians, our group of genetic counselors, physicians, and advanced-degree public health specialists bring a varied set of skills and expertise to 23andMe to promote the integration of genomics into care.

  • Noura Abul-Husn Noura Abul-Husn Vice President, Genomic Health
    Noura Abul-Husn

    Noura Abul-Husn

    Vice President, Genomic Health
    Dr. Noura Abul-Husn, MD, PhD is the Vice President of Genomic Health at 23andMe. She leads 23andMe’s clinical strategy to integrate consumer genetics into healthcare and provides genomic medicine expertise to direct company-wide health initiatives. In addition to her leadership role at 23andMe, Dr. Abul-Husn is an Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai.

    Dr. Abul-Husn is a physician scientist and expert in personalized healthcare and genomic medicine. She previously served as founding Chief of the Division of Genomic Medicine and Clinical Director of the Institute for Genomic Health at Mount Sinai, overseeing multi-disciplinary teams of clinicians and researchers to spearhead genomic research, education, and care delivery innovation. Prior to that, she served as Director of Translational Genetics at the Regeneron Genetics Center. She has spoken and published extensively on her research spanning genomic discovery, genomic medicine, and health equity.

    Dr. Abul-Husn is a double board-certified Internist and Medical Geneticist. She completed her MD, PhD, and residency at Mount Sinai in New York, and was elected to the Alpha Omega Alpha Medical Honor Society. She is the recipient of numerous awards, including a 40 under 40 Rising Star Award and the Dr. Michael S. Watson Genetic & Genomic Medicine Innovation Award from the ACMG Foundation for Genetic and Genomic Medicine.

  • Ryanne Wu Ryanne Wu Director, Genomic Medicine
    Ryanne Wu

    Ryanne Wu

    Director, Genomic Medicine
    Dr. Ryanne Wu is the Director of Genomic Medicine at 23andMe. She joined 23andMe in 2023. Dr. Wu provides a primary care perspective to product development as we guide customers from risk identification to risk mitigation strategies. Dr. Wu is also leading integration of evidence-based genetics-informed care into 23andMe’s Lemonaid telehealth platform.

    Dr. Wu brings over 15 years of clinical and research experience as a board-certified internal medicine physician and implementation scientist, developing and evaluating precision medicine interventions for primary care. Prior to 23andMe, she was an Associate Professor of Medicine at Duke University where she worked on projects related to family health history risk assessment and pharmacogenomics. She received her M.D. from the University of North Carolina at Chapel Hill and completed residency and chief residency in Internal Medicine at Georgetown University. She has a M.H.S. in Clinical Research from Duke University.

  • Stacey Detweiler Stacey Detweiler Manager, Genomic Health Programs and Medical Affairs
    Stacey Detweiler

    Stacey Detweiler

    Manager, Genomic Health Programs and Medical Affairs
    Stacey has been a part of the 23andMe team since 2016. Her years of experience in Medical Affairs help to shape 23andMe’s products and messaging through her clinical genetics lens. Stacey interacts with many different teams at the company to ensure that there is valid and clear communication about 23andMe products and services within the company and externally. Stacey’s past experience includes clinical and research experience as a genetic counselor in maternal fetal medicine clinics at Rutgers Robert Wood Johnson Medical School and the Palo Alto Medical Foundation. She has served in leadership for the Precision Medicine special interest group of the National Society of Genetic Counselors. Stacey earned her master’s degree in genetic counseling in 2012 from Arcadia University in Pennsylvania.
  • Marlena Orthlieb Marlena Orthlieb Medical Affairs Associate I, Clinical Genetics
    Marlena Orthlieb

    Marlena Orthlieb

    Medical Affairs Associate I, Clinical Genetics
    Marlena joined 23andMe in 2022. She provides clinical perspective and oversight toward identifying opportunities for and shaping company products, services, research efforts, communications, and claims. Marlena is a licensed and certified genetic counselor with past experience at Labcorp in a maternal fetal medicine clinic, providing preconception and perinatal counseling and offering support to healthcare providers regarding Women’s Health testing/results. Marlena has a passion for empowering individuals and striving towards better health outcomes for all communities through advancing genetic understanding and accessibility. Marlena earned her master’s degree in Genetic Counselor Studies in 2019 from the University of Wisconsin-Madison.
  • Katie Sagaser Katie Sagaser Genomic Health Education Manager
    Katie Sagaser

    Katie Sagaser

    Genomic Health Education Manager
    Katie recently joined 23andMe and provides medical and scientific outreach to key stakeholder groups, including healthcare providers and organizations, academic institutions, professional and scientific organizations, policy and governmental bodies, and consumer advocacy groups. Her professional interests center on the ways in which social media and e-commerce markets can enhance equitable access to genomics information. Prior to 23andMe, Katie was an Assistant Professor of Gynecology and Obstetrics in the Division of Maternal Fetal Medicine at the Johns Hopkins School of Medicine. She later served as the Director of Genetic Counseling at Juno Diagnostics and was part of the team that commercially launched the first at-home, capillary collected cell free DNA screen for fetal aneuploidy. Katie earned a M.S. in Genetic Counseling from The University of Texas M.D. Anderson Cancer Center UT Health Houston Graduate School of Biomedical Sciences, and was part of the inaugural cohort of the FemTech Medical Consultant Certificate program through FemInnovation.

* The 23andMe PGS test includes health predisposition and carrier status reports. Health predisposition reports include both reports that meet FDA requirements for genetic health risks and reports which are based on 23andMe research and have not been reviewed by the FDA. The test uses qualitative genotyping to detect select clinically relevant variants in the genomic DNA of adults from saliva for the purpose of reporting and interpreting genetic health risks and reporting carrier status. It is not intended to diagnose any disease. Your ethnicity may affect the relevance of each report and how your genetic health risk results are interpreted. Each genetic health risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person's overall risk of developing the disease. The test is not intended to tell you anything about your current state of health, or to be used to make medical decisions, including whether or not you should take a medication, how much of a medication you should take, or determine any treatment. Our carrier status reports can be used to determine carrier status, but cannot determine if you have two copies of any genetic variant. These carrier reports are not intended to tell you anything about your risk for developing a disease in the future, the health of your fetus, or your newborn child's risk of developing a particular disease later in life. For certain conditions, we provide a single report that includes information on both carrier status and genetic health risk. Warnings & Limitations: The 23andMe PGS Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants) is indicated for reporting of 44 variants in the BRCA1 and BRCA2 genes. The report describes if a person's genetic result is associated with an increased risk of developing breast cancer and ovarian cancer and may be associated with an increased risk for prostate cancer, pancreatic cancer, and potentially other cancers. The variants included in this report do not represent the majority of the BRCA1/BRCA2 variants in people of most ethnicities. This report does not include variants in other genes linked to hereditary cancers and the absence of variants included in this report does not rule out the presence of other genetic variants that may impact cancer risk. This report is for over-the-counter use by adults over the age of 18, and provides genetic information to inform discussions with a healthcare professional. The PGS test is not a substitute for visits to a healthcare professional for recommended screenings or appropriate follow-up. Results should be confirmed in a clinical setting before taking any medical action. For important information and limitations regarding each genetic health risk and carrier status report, visit 23andme.com/test-info/

**23andMe PGS Pharmacogenetics reports: The 23andMe test uses qualitative genotyping to detect 3 variants in the CYP2C19 gene, 2 variants in the DPYD gene and 1 variant in the SLCO1B1 gene in the genomic DNA of adults from saliva for the purpose of reporting and interpreting information about the processing of certain therapeutics to inform discussions with a healthcare professional. It does not describe if a person will or will not respond to a particular therapeutic. Our CYP2C19 Pharmacogenetics report provides certain information about variants associated with metabolism of some therapeutics and provides interpretive drug information regarding the potential effect of citalopram and clopidogrel therapy. Our SLCO1B1 Pharmacogenetics report provides certain information about variants associated with the processing of some therapeutics and provides interpretive drug information regarding the potential effect of simvastatin therapy. Our DPYD Pharmacogenetics report does not describe the association between detected variants and any specific therapeutic. Results for DPYD and certain CYP2C19 results should be confirmed by an independent genetic test prescribed by your own healthcare provider before taking any medical action. Warning: Test information should not be used to start, stop, or change any course of treatment and does not test for all possible variants that may affect metabolism or protein function. The PGS test is not a substitute for visits to a healthcare professional. Making changes to your current regimen can lead to harmful side effects or reduced intended benefits of your medication, therefore consult with your healthcare professional before taking any medical action. For important information and limitations regarding Pharmacogenetic reports, visit 23andme.com/test-info/pharmacogenetics/